Related Experiment Video
Updated: Mar 8, 2026
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
Identification of a selective inhibitor of transforming growth factor β-activated kinase 1 by biosensor-based
Takaaki Miura1, Atsushi Matsuo2, Terushige Muraoka2
1Research Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan.
Abstract:
Transforming growth factor-β activated kinase 1 (TAK1), a member of the mitogen-activated protein kinase kinase kinase family, plays an essential role in mediating signals from various pro-inflammatory cytokines and therefore may be a good target for developing anti-inflammation agents. Herein, we report our efforts to identify TAK1 inhibitors with a good selectivity profile with which to initiate medicinal chemistry. Instead of resorting to a high-throughput screening campaign, we performed biosensor-based biophysical screening for a limited number of compounds by taking advantage of existing knowledge on kinase inhibitors. Rather than focusing on one specific inhibition mode, we searched for three different types, Type I (ATP-competitive, DFG-in), Type II (DFG-out), and Type III binders (non-ATP competitive) in parallel, and succeeded in identifying candidates in all three categories efficiently and rapidly. Finally, the biosensor-based binding kinetics for the active and inactive forms of TAK1 were measured to prioritize the Type I and Type II inhibitors. The effort resulted in the identification of a new TAK1-selective Type I compound with a thienopyrimidine scaffold that served as a good starting point for medicinal chemistry.
Insights
Researchers identified novel inhibitors for transforming growth factor-β activated kinase 1 (TAK1), a key inflammation mediator. Using biosensor-based screening, they found Type I, II, and III TAK1 inhibitors, prioritizing a selective Type I thienopyrimidine compound for drug development.
Area of Science:
- Biochemistry
- Pharmacology
- Medicinal Chemistry
Background:
- Transforming growth factor-β activated kinase 1 (TAK1) is crucial in pro-inflammatory cytokine signaling.
- TAK1 represents a promising therapeutic target for anti-inflammation drug development.
Purpose of the Study:
- To identify selective inhibitors of TAK1 using a novel screening approach.
- To explore different inhibition modes, including Type I, Type II, and Type III binders.
Main Methods:
- Utilized biosensor-based biophysical screening with existing kinase inhibitor knowledge.
- Screened a limited compound set for multiple inhibition types (ATP-competitive, DFG-out, non-ATP competitive).
- Measured binding kinetics for active and inactive TAK1 forms to prioritize inhibitors.
Main Results:
- Successfully identified TAK1 inhibitor candidates across all three targeted inhibition types.
- Discovered a new TAK1-selective Type I inhibitor featuring a thienopyrimidine scaffold.
- Demonstrated efficient and rapid identification of diverse TAK1 inhibitor classes.
Conclusions:
- Biosensor-based screening offers an efficient alternative to high-throughput screening for kinase inhibitor discovery.
- The identified thienopyrimidine compound provides a valuable starting point for medicinal chemistry efforts targeting TAK1.
- This study highlights a successful strategy for identifying selective inhibitors for complex kinase targets.
